<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152852">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670890</url>
  </required_header>
  <id_info>
    <org_study_id>pumch-neurosurgery-01</org_study_id>
    <nct_id>NCT01670890</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas</brief_title>
  <official_title>Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant
      gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.
      Up to now, the prognosis of recurrent gliomas is very pessimistic and the standard treatment
      procedure has not been established yet.

      The prospective,multicentre phase II clinical study is to evaluate the efficacy and safety
      of TMZ and CDDP in patients with recurrent malignant gliomas
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>over all survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Malignant Gliomas</condition>
  <arm_group>
    <arm_group_label>TMZ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients were treated with TMZ alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMZ plus CDDP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients were treated with TMZ plus CDDP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ</intervention_name>
    <description>patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles</description>
    <arm_group_label>TMZ group</arm_group_label>
    <other_name>temozolomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ plus CDDP</intervention_name>
    <description>patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles</description>
    <arm_group_label>TMZ plus CDDP group</arm_group_label>
    <other_name>temozolomide and cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age&gt;=18 and &lt;=70years old

          -  Histological diagnosis of malignant gliomas(WHO III or IV)

          -  The status of methylation of promotor of MGMT should be detected.

          -  The time to be enrolled should be more than 90 days after the irradiation.

          -  The patients with recurrent gliomas were treated with non-dose-dense TMZ therapy
             before enrollment.

          -  Performance status(Karnofsky index)&gt;=60

          -  Life expectancy more than 3 months

        Exclusion Criteria:

          -  Ages:&lt; 18 years or &gt; 70 years

          -  Abnormal function of liver or renal(value more than 1.5 fold normal upper limit )

          -  Blood routing: Hb &lt; 100g/l， WBC ＜ 4.0×109/l; PLT &lt; 100×109/l

          -  Pregnant or lactating women

          -  Allergic to administered drugs

          -  Radiation treatment in the previous 90 days or stereotactic radiation surgery within
             60 days before enrollment

          -  The patients with recurrent gliomas were treated with dose-dense TMZ therapy before
             enrollment.

          -  Life expectancy less than 3 months

          -  Participation in other clinical trials in the 90previous days before enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wang renzhi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wang renzhi, MD</last_name>
    <phone>86-010-69156071</phone>
    <email>wangrz@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang yu, MD</last_name>
    <phone>86-010-69156071</phone>
    <email>kingrichwy@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang ren zhi, MD</last_name>
      <phone>86-010-69156071</phone>
      <email>wangrz@126.com</email>
    </contact>
    <investigator>
      <last_name>Ma wen bin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>wang yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital Affiliated to Capital Medial University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang tao, MD</last_name>
      <phone>86-010-67021832</phone>
      <email>jiangtao369@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin medical university general university</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang xue jun, MD</last_name>
      <email>ydenny@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 21, 2012</lastchanged_date>
  <firstreceived_date>August 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>temozolomide(TMZ)</keyword>
  <keyword>cisplatin(CDDP)</keyword>
  <keyword>recurrent malignant gliomas</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
